The International Library of Ethics, Law and Technology 14 Deborah Mascalzoni Editor Ethics, Law and Governance of Biobanking National, European and International Approaches Ethics, Law and Governance of Biobanking The International Library of Ethics, Law and Technology VOLUME 14 Editors Anthony Mark Cutter, Lancashire, UK Bert Gordijn, Ethics Institute, Dublin City University, Ireland Gary E. Marchant, Center for the Study of Law, Science, and Technology, Arizona State University, USA Colleen Murphy, University of Illinois at Urbana-Champaign, Urbana, IL, USA Alain Pompidou, European Patent Office, Munich, Germany Sabine Roeser, Dept. Philosophy, Delft University of Technology, Delft, The Netherlands Editorial Board Dieter Birnbacher, Institute of Philosophy, Heinrich-Heine-Universität, Germany Roger Brownsword, King’s College London, UK Ruth Chadwick, ESRC Centre for Economic & Social Aspects of Genomics, Cardiff, UK Paul Stephen Dempsey, Institute of Air & Space Law, Université de Montréal, Canada Michael Froomkin, University of Miami Law School, FL, USA Serge Gutwirth, Vrije Universiteit, Brussels, Belgium Henk ten Have, Duquesne University, Pittsburgh, USA Søren Holm, University of Manchester, UK George Khushf, Center for Bioethics, University of South Carolina, USA Justice Michael Kirby, High Court of Australia, Canberra, Australia Bartha Maria Knoppers, Université de Montréal, Canada David Krieger, The Waging Peace Foundation, CA, USA Graeme Laurie, AHRC Centre for Intellectual Property and Technology Law, UK René Oosterlinck, European Space Agency, Paris Edmund Pellegrino, Kennedy Institute of Ethics, Georgetown University, USA John Weckert, School of Information Studies, Charles Sturt University, Australia More information about this series at http://www.springer.com/series/7761 Deborah Mascalzoni Editor Ethics, Law and Governance of Biobanking National, European and International Approaches 1 3 Editor Deborah Mascalzoni Centre for Biomedicine European Academy Bolzano Bolzano Italy ISSN 1875-0044 ISSN 1875-0036 (electronic) The International Library of Ethics, Law and Technology ISBN 978-94-017-9572-2 ISBN 978-94-017-9573-9 (eBook) DOI 10.1007/978-94-017-9573-9 Library of Congress Control Number: 2014959850 Springer Dordrecht Heidelberg New York London © Springer Science+Business Media Dordrecht 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Springer Science+Business Media B.V. Dordrecht is part of Springer Science+Business Media (www.springer.com) Acknowledgments This book has a very long and complex story. I wish to thank all the authors for their great work and even greater patience. I am also very grateful to Mirko Ancillotti for his support and help. v Contents Ethics Law and Governance of Biobanking: A Very Complex Normative Puzzle .............................................. 1 Deborah Mascalzoni Biobanks: A Definition .......................................... 15 Barbara Parodi A Participatory Space Beyond the “Autonomy Versus Property” Dichotomy ........................................... 21 Mariachiara Tallacchini Intellectual Property and Biobanks ............................... 39 Naomi Hawkins Consent, Privacy and Property in the Italian Biobanks Regulation: A Hybrid Model Within EU? .......................... 53 Matteo Macilotti, Simone Penasa and Marta Tomasi Data Protection Principles and Research in the Biobanks Age ......... 79 Roberto Lattanzi The New General Data Protection Regulation—Where Are We Are and Where Might We Be Heading? ......................... 95 Jane Reichel and Anna-Sara Lind The Tension Between Data Sharing and the Protection of Privacy in Genomics Research ................................. 101 Jane Kaye vii viii Contents Incidental Findings: The Time Is not yet Ripe for a Policy for Biobanks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121 Jennifer Viberg, Mats G. Hansson, Sophie Langenskiöld and Pär Segerdahl Biobanking Across Borders: The Challenges of Harmonisation ........ 133 Ruth Chadwick and Heather Strange Governing Biobanks Through a European Infrastructure ............. 139 Emmanuelle Rial-Sebbag and Anne Cambon-Thomsen EU Governance for Research and Ethics in Biobanks ................ 153 Jane Reichel A Bold Experiment: Iceland’s Genomic Venture ..................... 187 David Winickoff The Estonian Genome Center, University of Tartu ................... 211 Aime Keis Management of the Ethical Aspects of a Local Mental Diseases Biobank for Research Purposes: The Italian Experience ...... 219 Corinna Porteri Biobank Governance in Spain: From the Autonomy of Research Ethics Committees to the Autonomy of Lay People ........ 227 Antonio Casado da Rocha Public Deliberation and the Role of Stakeholders as a New Frontier in the Governance of Science: The British Columbia Biobank Deliberation and the DePGx Project ....................... 241 Claudio Corradetti and Gillian Bartlett Making Researchers Moral ...................................... 261 Linus Johnsson, Stefan Eriksson, Gert Helgesson and Mats G. Hansson Ethics Law and Governance of Biobanking: A Very Complex Normative Puzzle Deborah Mascalzoni The Food and Drug Administration in the US recently granted premarket c learance for a DNA sequencing platform with increased diagnostic power. Francis Collins et al. stated in an editorial in the New England Journal of Medicine that this approval may open the door “for the development and use of innumerable new genome-based tests” (Collins et al. 2013). Collins et al. called the approval “a landmark move that will finally open the way to realize the promise of personal- ized medicine” (Collins et al. 2013). We are moving into a world where whole-genome scanning of individual DNA samples will start to become routine in medical research and clinical practice; proposals for routine screening of genomic profiles have already appeared in the public policy arena. The borders between medical research and clinical practice are to a certain extent blurring, so that research sequencing platforms are starting to gain clinical validity and clinical practice is beginning to rely more immediately and more closely on research results. Biobank research and genomic information are reshaping our notions of health and medicine and offering the promise of more tailored medical treatment. The cost effectiveness of these treatments and of pharmacogenomics in general are part of this conversation, but it has been claimed that the way forward relies on bio-specimen research. In Europe, the investments in research infrastructure and the linkages between existing biobanks and biomedical projects are extensively supported by public funding. The EU Seventh Framework funding programme invested heavily in the D. Mascalzoni (*) Centre for Biomedicine, European Academy of Bolzano, Bolzano, Italy e-mail: [email protected] © Springer Science+Business Media Dordrecht 2015 1 D. Mascalzoni (ed.), Ethics, Law and Governance of Biobanking, The International Library of Ethics, Law and Technology 14, DOI 10.1007/978-94-017-9573-9_1 2 D. Mascalzoni creation of network infrastructures and working consortia in order to facilitate the genomics movement on a large scale, and the research and innovation programme Horizon 2020 seems to be following the same philosophy. The rapid pace of technology development in genome sequencing has an impact on how we think about biobank-based research regulation and health regulation. Thus, for example, the advances in bioinformatics and the augmented power of computing technologies together with the availability of widespread access to different network facilities have completely reshaped our notion of infor- mational risk, leading to the conclusion that the very idea of anonymity in research may be a fairy tale. How should these developments impact the current regulatory approaches, which rely heavily on anonymity and confidentiality in research? In the European parliament, the fear that the increased computer processing power associated with Web 2.0 internet technologies could impact individual privacy interests led to the proposal for a General Data Protection Regulation (GDPR) in January 2013, which initially suggested very strict rules for research. This proposal was severely criticised by patient associations, and there were widespread comments from scientists, scholars and professional associations who feared its possible impact on research. While the first impression is that regulations follow scientific development, in fact, there are very complex dynamics in the co-production of bio-objects and regulatory approaches. Just as regulations impact research, research impacts regu- lation and governance approaches. Bottom-up approaches and self-regulation are constantly informing scientific practice. In a highly complex relationship, social values, existing rules, health expectations and science each play a role in reshaping the regulatory context. The existing wealth of regulations on local, regional, national and interna- tional levels creates a complex picture that must be deciphered in order to c onduct research. Binding legal rules need to be acknowledged together with ethical requirements and non-binding professional guidelines that sometimes overlap and diverge. This book outlines the current developing situation with respect to biobanking regulations. The very definition of what constitutes a biobank is not unequivocal. Barbara Parodi explains the differences in the lexicon. She has explored the main literature in the field to provide a glossary that will help to map the complexity of the existing reality. It appears that the terms biorepository, biological resource centre and biobank can refer to very different structured collections of biologi- cal samples and associated data. They can include human tissues, animal tissues, cells, bacterial cultures and even environmental samples. These terms are often confused and sometimes misplaced in the literature. The associated regulations pertain to the kind of materials collected and the possible uses of those materi- als. Therefore human tissues collected for clinical use will be associated with a different legal and ethical framework than animal cell lines collected for research purposes. Relevant aspects such as proprietary rights, patenting, etc. will therefore have a very different basis. Barbara Parodi looks at how the various biobanks and